CJC-1295 research guide for Monash. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
CJC-1295 Near Monash — What Researchers Need to Know
CJC-1295 isn't found on pharmacy shelves in Monash or anywhere else for that matter — this is a specialist compound distributed through a dedicated online market. This concentration of supply in online vendors is actually an advantage for quality — top vendors compete on lab-verified purity in ways brick-and-mortar outlets simply cannot. The primary quality indicators for CJC-1295 are HPLC purity ≥98%, molecular identity established via mass spectrometry, and a bacterial endotoxin panel — all documented in a lot-traced Certificate of Analysis. The sections below cover what Monash researchers need to know about sourcing, verifying, and handling CJC-1295 for research purposes.
What Studies Say About CJC-1295
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Monash studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
Sourcing Research-Grade CJC-1295
The first step for any Monash researcher sourcing CJC-1295 is locating suppliers that experienced researchers actively recommend — commercial rankings reflect SEO budgets rather than product quality. Mass spectrometry in the COA establishes that the main HPLC peak is actually CJC-1295 and not a different peptide of similar polarity — HPLC purity alone does not confirm what the compound actually is. For Monash researchers evaluating vendors with limited track records: a test quantity before committing to research volumes before scaling up your order is standard practice in the community. For Monash researchers making a first CJC-1295 purchase: verify the vendor against this framework, start with a modest quantity, and check that batch numbers on your vial match the COA before use.
Order CJC-1295 — ships to Monash
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not undergone the clinical trial process required for pharmaceutical approval — its safety profile is based on preclinical research and limited human studies. Proper handling of CJC-1295 requires strict sterile technique during reconstitution — alcohol-swabbed septum, fresh needles, clean working environment — and consistent cold chain handling. Verify the endotoxin level in your CJC-1295 batch COA before any injectable research application — look for results reported in endotoxin units per mg or mL and confirm they fall within appropriate thresholds. The research literature on CJC-1295 should be read critically before designing any protocol — study methodologies, dosing, and endpoints vary significantly and results do not always generalise across models.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
